Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS, Corgentech terminate vein graft deal

Executive Summary

Bristol-Myers Squibb and Corgentech (intracellular disease therapies) are collaborating to develop and commercialize Corgentech's drug candidate E2F Decoy (edifoligide sodium), which is a new class of therapeutics to treat complications related to coronary artery and peripheral arterial bypass surgeries.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register